Drug Profile
YYB 103
Alternative Names: CLM-103; YYB103Latest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator Yooyoung Pharmaceutical
- Class
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioblastoma
- Discontinued Amyotrophic lateral sclerosis
Most Recent Events
- 22 Sep 2022 Discontinued - Preregistration for Amyotrophic lateral sclerosis in South Korea (unspecified route)
- 18 Jul 2022 Phase-I clinical trials in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in South Korea (IV) (NCT05540873)
- 08 Nov 2021 Pharmacodynamics data from a preclinical study in Glionlastoma released by Cellamed (Cellamed pipeline, September 2022)